Topic suggestions are now open for the 4th PAS Congress, February 4-6, 2022. All topic suggestions are due by March… https://t.co/vtAn5SOROC–@movedisorder
Our goal is to provide guidance to clinicians, policy makers and the PD community on how COVID-19 has transformed t… https://t.co/03yqKtW9wZ–@ParkinsonDotOrg
Our scientists are working around the clock to keep accelerating Parkinson's research toward a cure. But MJFF also… https://t.co/x36vufTuoC–@MichaelJFoxOrg
Register now for the latest MDS Presidential Perspective Webinar. This free lecture is presented by Joseph Jankovic… https://t.co/D7MCTbaMZt–@movedisorder
RT @TBHTimeMatters: We are delighted to share 'Personalized plans, blood biomarkers and early conversations' - a report of our recent #Thin… –@MichaelJFoxOrg
The 2020 Michael J. Fox Foundation Virtual 5K/10K was an incredible demonstration of what our community can do when… https://t.co/sGtUGMhzkJ–@MichaelJFoxOrg
Abstract submission for the MDS Virtual Congress 2021 is now open. The deadline to submit abstracts is March 15, 20… https://t.co/1LYPowujdx–@movedisorder
Backed by The Michael J. Fox Foundation funding, biotechnology company MODAG recently launched a trial of anle138b… https://t.co/qjJnJQSTIo–@MichaelJFoxOrg
RT @RachelDolhunMD: Some people with #COVID-19 report memory and thinking changes, such as brain fog or difficulty focusing. What does this… –@MichaelJFoxOrg
Using the MDS-UPDRS remotely or when the pandemic has impacted your ability to obtain all values can be challenging… https://t.co/9QkfMbR7Bw–@movedisorder
RT @MichaelJFoxOrg: As #COVID19 vaccine distribution proceeds, we continue to share urgent updates with our community. Read our blog for th… –@movedisorder
The MDS Scientific Issues Committee has compiled a slide deck, summarizing information on development, safety data,… https://t.co/7eaovQnQyc–@movedisorder
46 patients from the US, UK, and Canada have been taking part in a clinical trial in Toronto in hopes of finding a cure for Huntington's disease. The therapy targets and stifles the mutant huntingtin (HTT) gene that causes the toxic proteins responsible for the disease. Scientists around the world remain hopeful as the trial shifts into Phase 3, which will involve an injection in the patient's spine that could stop all negative activity of the mutant HTT gene.